NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

Published:2022-02 Issue:2 Volume:20 Page:106-117
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Greenberg Peter L.¹,Stone Richard M.²,Al-Kali Aref³,Bennett John M.⁴,Borate Uma⁵,Brunner Andrew M.⁶,Chai-Ho Wanxing⁷,Curtin Peter⁸,de Castro Carlos M.⁹,Deeg H. Joachim¹⁰,DeZern Amy E.¹¹,Dinner Shira¹²,Foucar Charles¹³,Gaensler Karin¹⁴,Garcia-Manero Guillermo¹⁵,Griffiths Elizabeth A.¹⁶,Head David¹⁷,Jonas Brian A.¹⁸,Keel Sioban¹⁰,Madanat Yazan¹⁹,Maness Lori J.²⁰,Mangan James²¹,McCurdy Shannon²²,McMahon Christine²³,Patel Bhumika²⁴,Reddy Vishnu V.²⁵,Sallman David A.²⁶,Shallis Rory²⁷,Shami Paul J.²⁸,Thota Swapna²⁹,Varshavsky-Yanovsky Asya Nina³⁰,Westervelt Peter³¹,Hollinger Elizabeth³²,Shead Dorothy A.³²,Hochstetler Cindy³²

Affiliation:

1. 1Stanford Cancer Institute;

2. 2Dana-Farber/Brigham and Women’s Cancer Center;

3. 3Mayo Clinic Cancer Center;

4. 4University of Rochester;

5. 5The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute;

6. 6Massachusetts General Hospital Cancer Center;

7. 7UCLA Jonsson Comprehensive Cancer Center;

8. 8City of Hope National Medical Center;

9. 9Duke Cancer Institute;

10. 10Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

11. 11The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

12. 12Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

13. 13University of Michigan Rogel Cancer Center;

14. 14UCSF Helen Diller Family Comprehensive Cancer Center;

15. 15The University of Texas MD Anderson Cancer Center;

16. 16Roswell Park Comprehensive Cancer Center;

17. 17Vanderbilt-Ingram Cancer Center;

18. 18UC Davis Comprehensive Cancer Center;

19. 19UT Southwestern Simmons Comprehensive Cancer Center;

20. 20Fred & Pamela Buffett Cancer Center;

21. 21UC San Diego Moores Cancer Center;

22. 22Abramson Cancer Center at the University of Pennsylvania;

23. 23University of Colorado Cancer Center;

24. 24Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

25. 25O'Neal Comprehensive Cancer Center at UAB;

26. 26Moffitt Cancer Center;

27. 27Yale Cancer Center/Smilow Cancer Hospital;

28. 28Huntsman Cancer Institute at the University of Utah;

29. 29St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

30. 30Fox Chase Cancer Center;

31. 31Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; and

32. 32National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/2/article-p106.xml

Reference68 articles.

1. Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome;Vicente;Haematologica,2020

2. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study;Steensma;J Clin Oncol,2021

3. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

4. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome [abstract];Zeidan;Blood,2019

5. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study;Garcia-Manero;Blood,2020

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

2. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes;Cancer Treatment Reviews;2024-02

3. Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders;Best Practice & Research Clinical Haematology;2024-02

4. The difference of double-positive T cells and double-negative-T cells in myeloid neoplasms before and after chemotherapy, and after COVID-19 infection;2024-01-19

5. How I diagnose and treat thrombocytopenia in geriatric patients;Blood;2024-01-18